Nucleic acid-based gene-silencing molecules as potential antiviral therapeutics

Ji Yuan, Zhongbin Chen, Paul Cheung, David Chau, Decheng Yang

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The sequencing of many human viral genomes and the elucidation of molecular mechanisms of viral replication as well as signal transduction pathways involved in viral pathogenesis have provided unprecedented opportunities for the development of new therapeutics. One type of the most promising molecules in drug development is the nucleic-acid-based therapeutics, including antisense oligodeoxyribonucleotides (AODN), ribozymes, DNAzyme and small interfering RNA (siRNA). AODNs have shown great potential as powerful tools in gene functional studies, as well as highly selective therapeutic agents in drug development. Although several problems have been encountered such as toxicity, non-stability, side effects, and low intracellular uptake, there has been at least one antisense drug approved for the treatment of cytomegalovirus retinitis, and over twenty other antisense candidates are undergoing clinical trials. Ribozymes and DNAzymes, by binding to substrate RNA through base pairing, offer sequence-specific cleavage of disease-associated RNA transcripts and show great potential for development of novel antiviral agents. RNA interference has emerged as a novel tool that offers great hope and promise to study gene functions and to develop therapeutics against viral infection. This powerful antiviral effect is mediated by siRNAs that target the viral mRNA for degradation by cellular enzymes. The potential of siRNA to treat or prevent diseases in clinical settings remains to be proven. This article first overviews current nucleic acid-based approaches in gene silencing, and then focuses on the potential applications in antiviral therapy including our own data on coxsackieviral infection.

Original languageEnglish (US)
Pages (from-to)323-333
Number of pages11
JournalDrug Design Reviews Online
Volume2
Issue number4
DOIs
StatePublished - Jun 1 2005

Fingerprint

Gene Silencing
Nucleic Acids
Antiviral Agents
Catalytic DNA
Catalytic RNA
Small Interfering RNA
Antisense Oligodeoxyribonucleotides
Pharmaceutical Preparations
RNA
Cytomegalovirus Retinitis
Therapeutics
Viral Genome
RNA Stability
Human Genome
Virus Diseases
RNA Interference
Base Pairing
Genes
Signal Transduction
Clinical Trials

Keywords

  • Antisense ODN
  • Antiviral agents
  • Coxsackievirus B3
  • DNAzyme
  • Ribozymes
  • Small interfering RNA

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Nucleic acid-based gene-silencing molecules as potential antiviral therapeutics. / Yuan, Ji; Chen, Zhongbin; Cheung, Paul; Chau, David; Yang, Decheng.

In: Drug Design Reviews Online, Vol. 2, No. 4, 01.06.2005, p. 323-333.

Research output: Contribution to journalReview article

Yuan, Ji ; Chen, Zhongbin ; Cheung, Paul ; Chau, David ; Yang, Decheng. / Nucleic acid-based gene-silencing molecules as potential antiviral therapeutics. In: Drug Design Reviews Online. 2005 ; Vol. 2, No. 4. pp. 323-333.
@article{71762bd5d26e473486fa68a3fcf2318a,
title = "Nucleic acid-based gene-silencing molecules as potential antiviral therapeutics",
abstract = "The sequencing of many human viral genomes and the elucidation of molecular mechanisms of viral replication as well as signal transduction pathways involved in viral pathogenesis have provided unprecedented opportunities for the development of new therapeutics. One type of the most promising molecules in drug development is the nucleic-acid-based therapeutics, including antisense oligodeoxyribonucleotides (AODN), ribozymes, DNAzyme and small interfering RNA (siRNA). AODNs have shown great potential as powerful tools in gene functional studies, as well as highly selective therapeutic agents in drug development. Although several problems have been encountered such as toxicity, non-stability, side effects, and low intracellular uptake, there has been at least one antisense drug approved for the treatment of cytomegalovirus retinitis, and over twenty other antisense candidates are undergoing clinical trials. Ribozymes and DNAzymes, by binding to substrate RNA through base pairing, offer sequence-specific cleavage of disease-associated RNA transcripts and show great potential for development of novel antiviral agents. RNA interference has emerged as a novel tool that offers great hope and promise to study gene functions and to develop therapeutics against viral infection. This powerful antiviral effect is mediated by siRNAs that target the viral mRNA for degradation by cellular enzymes. The potential of siRNA to treat or prevent diseases in clinical settings remains to be proven. This article first overviews current nucleic acid-based approaches in gene silencing, and then focuses on the potential applications in antiviral therapy including our own data on coxsackieviral infection.",
keywords = "Antisense ODN, Antiviral agents, Coxsackievirus B3, DNAzyme, Ribozymes, Small interfering RNA",
author = "Ji Yuan and Zhongbin Chen and Paul Cheung and David Chau and Decheng Yang",
year = "2005",
month = "6",
day = "1",
doi = "10.2174/1567269054087640",
language = "English (US)",
volume = "2",
pages = "323--333",
journal = "Drug Design Reviews Online",
issn = "1567-2697",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Nucleic acid-based gene-silencing molecules as potential antiviral therapeutics

AU - Yuan, Ji

AU - Chen, Zhongbin

AU - Cheung, Paul

AU - Chau, David

AU - Yang, Decheng

PY - 2005/6/1

Y1 - 2005/6/1

N2 - The sequencing of many human viral genomes and the elucidation of molecular mechanisms of viral replication as well as signal transduction pathways involved in viral pathogenesis have provided unprecedented opportunities for the development of new therapeutics. One type of the most promising molecules in drug development is the nucleic-acid-based therapeutics, including antisense oligodeoxyribonucleotides (AODN), ribozymes, DNAzyme and small interfering RNA (siRNA). AODNs have shown great potential as powerful tools in gene functional studies, as well as highly selective therapeutic agents in drug development. Although several problems have been encountered such as toxicity, non-stability, side effects, and low intracellular uptake, there has been at least one antisense drug approved for the treatment of cytomegalovirus retinitis, and over twenty other antisense candidates are undergoing clinical trials. Ribozymes and DNAzymes, by binding to substrate RNA through base pairing, offer sequence-specific cleavage of disease-associated RNA transcripts and show great potential for development of novel antiviral agents. RNA interference has emerged as a novel tool that offers great hope and promise to study gene functions and to develop therapeutics against viral infection. This powerful antiviral effect is mediated by siRNAs that target the viral mRNA for degradation by cellular enzymes. The potential of siRNA to treat or prevent diseases in clinical settings remains to be proven. This article first overviews current nucleic acid-based approaches in gene silencing, and then focuses on the potential applications in antiviral therapy including our own data on coxsackieviral infection.

AB - The sequencing of many human viral genomes and the elucidation of molecular mechanisms of viral replication as well as signal transduction pathways involved in viral pathogenesis have provided unprecedented opportunities for the development of new therapeutics. One type of the most promising molecules in drug development is the nucleic-acid-based therapeutics, including antisense oligodeoxyribonucleotides (AODN), ribozymes, DNAzyme and small interfering RNA (siRNA). AODNs have shown great potential as powerful tools in gene functional studies, as well as highly selective therapeutic agents in drug development. Although several problems have been encountered such as toxicity, non-stability, side effects, and low intracellular uptake, there has been at least one antisense drug approved for the treatment of cytomegalovirus retinitis, and over twenty other antisense candidates are undergoing clinical trials. Ribozymes and DNAzymes, by binding to substrate RNA through base pairing, offer sequence-specific cleavage of disease-associated RNA transcripts and show great potential for development of novel antiviral agents. RNA interference has emerged as a novel tool that offers great hope and promise to study gene functions and to develop therapeutics against viral infection. This powerful antiviral effect is mediated by siRNAs that target the viral mRNA for degradation by cellular enzymes. The potential of siRNA to treat or prevent diseases in clinical settings remains to be proven. This article first overviews current nucleic acid-based approaches in gene silencing, and then focuses on the potential applications in antiviral therapy including our own data on coxsackieviral infection.

KW - Antisense ODN

KW - Antiviral agents

KW - Coxsackievirus B3

KW - DNAzyme

KW - Ribozymes

KW - Small interfering RNA

UR - http://www.scopus.com/inward/record.url?scp=23944507112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944507112&partnerID=8YFLogxK

U2 - 10.2174/1567269054087640

DO - 10.2174/1567269054087640

M3 - Review article

AN - SCOPUS:23944507112

VL - 2

SP - 323

EP - 333

JO - Drug Design Reviews Online

JF - Drug Design Reviews Online

SN - 1567-2697

IS - 4

ER -